RecruitingPhase 3NCT07746544

Study of Secutrelvir in Participants With COVID-19

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19

Sponsor

Shionogi

Enrollment

1,200 participants

Start Date

Aug 5, 2026

Study Type

INTERVENTIONAL

Conditions

COVID-19

Summary

The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.

Eligibility

Min Age: 12 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Secutrelvir for people with covid-19. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.